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A new poly(amidoamine)-cholesterol (PAA-cholesterol) conjugate was synthesized, characterized and used to produce
nanoparticles by the electrospraying technique. The electrospraying is a method of liquid atomization that consists in the
dispersion of a solution into small charged droplets by an electric field. Tuning the electrospraying process parameters spherical
PAA-chol nanoparticles formed. The PAA-cholesterol nanoparticles showed sizes lower than 500 nm and spherical shape. The
drug incorporation capacity was investigated using tamoxifen, a lipophilic anticancer drug, as model drug. The incorporation of
the tamoxifen did not aﬀect the shape and sizes of nanoparticles showing a drug loading of 40%. Tamoxifen-loaded nanoparticles
exhibited a higher dose-dependent cytotoxicity than free tamoxifen, while blank nanoparticles did not show any cytotoxic eﬀect at
the same concentrations. The electrospray technique might be proposed to produce tamoxifen-loaded PAA-chol nanoparticle in
powder form without any excipient in a single step.
1. Introduction
Polymeric nanoparticles focused a great attention in the
biomedical field as delivery systems for active molecules.
These nanoparticles have the potential to act as a reservoir
of drugs, protecting them from the environments and con-
trolling their release rates, thereby enhancing the biological
activity and decreasing the adverse side eﬀects [1–4].
Various procedures have been proposed in the literature
for the fabrication of polymeric nanoparticles and the
most used are based on emulsion techniques. However
novel methods are attracting increasing attention. One of
such is electrohydrodynamic atomization (EHDA), a process
with many applications, such as manufacturing nanoscale
polymer fibres or thin film and particulate systems [5, 6].
Particularly, EHDA in the cone jet mode (electrospraying)
has been previously studied to produce polymeric particles
which can be used as drug delivery systems [7, 8]. The
electrospray is a method of liquid atomization that consists
in the dispersion of a solution into small charged droplets by
an electric field.
Electrospraying is a one-step technique with the potential
to ensure particle with reproducible sizes and morphology
with a narrow size distribution in the micro- and nanometer
range by selecting the proper process conditions.
The principle of electrospraying is based on the capacity
of an electric field to deform the interface of a droplet as
reported by Jaworek [9]. Particularly, when an electric field
is applied on a droplet, it generates an electrostatic force
inside the droplets able to overcome the cohesive force of
the droplet. Thus the droplet will undergo break-up into
smaller droplets in the micro-nanoscale range. Depending
on the spraying mode, droplets can be smaller than 100 nm
with low standard deviation. This charged aerosol is self-
dispersing preventing the droplets from coalescence. This
phenomenon is known as Taylor Cone and consists in the
progressive shrinking of the charged droplet into a cone from
which smaller charged droplets will be ejected [10].
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The electrospraying process is simple; it consists in the
loading of a polymer solution in a syringe which is infused at
constant rate by a pump through a highly charged capillary,
forming a droplet at the tip. A dropled formed at the capillary
tip and after the droplet detached from the Taylor cone
the solvent evaporates generating solid particles. During the
electrospraying process there are several parameters which
can aﬀect particle sizes, size distribution, encapsulation
eﬃciency, and in vitro release profiles. These include voltage,
flow rate, distance from the collector, solvent, and needle
gauge. Consequently the number of parameters to be
considered to obtain a reproducible process is several and the
optimization is complex.
Previously we have tuned the electrospraying process
parameters for producing lipid-based micro-nanoparticles
[11]. Narrowly dispersed spherical particles with sizes lower
than 1 μm were obtained using stearic acid and ethylcellulose
in a 4.5 : 0.5 ratio (w/w).
The aim of this work was to investigate the feasibility of
obtaining solid polymeric nanoparticles using a cholesterol
polyamidoamines (PAAs) conjugate by electrospraying.
PAAs are synthetic degradable polymers obtained by
Micheal-type polyaddition of primary or bis-secondary
amines to bis-acrylamides [12]. All PAAs contain amide and
tertiary amine groups along the main chain.
In PAA-cholesterol conjugates an active substituent was
bound to the polymer chain through a disulfide linkage
that is known to be stable in the bloodstream but amenable
to reductive cleavage inside cells. Preliminary cytocompat-
ibility tests demonstrated that all prepared PAA-cholesterol
samples are cytocompatible and thus show potential for
biotechnological and pharmaceutical applications [13]. In
this work a new PAA conjugate was used to prepare solid
nanoparticles by electrospraying as potential drug delivery
systems. The goal of the work was to develop a reproducible
one-step process to obtain spherical solid PAA-cholesterol
nanoparticles with homogeneous size distribution by elec-
trospraying. Moreover cytotoxicity of nanoparticles was
assessed in order to avoid the possibility of toxic residues after
the electrospraying process.
Tamoxifen, a lipophilic anticancer drug, was used as
model drug to study the encapsulation capacity of the
PAA conjugate. Tamoxifen is a selective estrogen receptor
modulator widely used in breast cancer therapy. The drug
can produce serious side eﬀects, as thrombosis, pulmonary
embolism, and modification in liver enzyme levels. In addi-
tion cancer cells can develop resistance against tamoxifen,
and it may initiate endometrial cancer. The encapsulation of
tamoxifen in a drug delivery system might provide a better
drug release profile potentially preventing the development
of cell resistance [14].
2. Material and Methods
2.1. Material. n-Pentanol was from Merck (Darmstadt,
Germany). Tamoxifen, sodium citrate, Rhodamine B, and
citric acid were from Sigma Aldrich (St. Louis, USA).
High voltage
Figure 1: Scheme of the apparatus for electrospraying.
Cellulose dialysis membrane (Spectra/Por dialysis mem-
brane) was from Spectrum Laboratories, Inc (Canada). 2,2-
bis(acrylamido)acetic acid and 1,4-bis(acryloil)piperazine
were synthesized as previously described [15, 16]. All
reagents are of analytical grade.
2.2. Cells. Both MCF-7 (a human breast adenocarcinoma
cell line) and Vero (an African green monkey kidney cell line)
were maintained in Minimum Essential Medium (PAA, 4061
Pasching, Austria) with 10% Fetal Calf Serum (Gibco/BRL)
and 1% Zell Shield (Minerva Biolabs GmbH, Berlin).
Subculturing of cells was carried out by trypsinization and
by diluting cells with fresh medium. Cells were grown in the
presence of 5% CO2 at 37◦C.
2.3. Electrospraying Setup. The apparatus for electrospraying
comprises a 2.5 mL syringe connected to an infusion pump
(KDS 100, Biological Instruments, VA, Italy). A Teflon pipe
connects the syringe to the tip of a metal capillary (ID:
0.6 mm) (Figure 1). An aluminium foil collector is placed
opposite the capillary as counter electrode. A strong electric
field was applied between the tip and the collector. The
distance from metal tip to collecting plate varied from 20 to
15 cm.
The solution contained in the syringe is supplied to
the nozzle at a flow rate forming a droplet. The electric
field induces charges on the droplet surface. A liquid jet
occurs that can break up in droplets with a narrow size
distribution. Solid particles formed by solvent evaporation
from the droplets which travel through the electric field.
2.4. Preparation and Characterization of PAA-Cholesterol
Conjugate. A PAA-cholesterol conjugate derived from two
diﬀerent bis-acrylamides, namely 2,2-bis(acrylamido)acetic
acid and 1,4-bis(acryloil)piperazine, with a cholesterol con-
tent of 8.1% w/w and Mw = 13000 was obtained (Figure 2).
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The reaction pathway consisted of three steps: (1) the synthe-
sis of a PAA-based hydrogel containing cystamine as cross-
linker, (2) a disulfide-exchange reaction with 2,2′-dipyridyl
disulfide that leads to soluble linear polymers containing
ethenyldithiopyridine moieties, and (3) a thiol-exchange
reaction between thiocholesterol and the dithiopyridine
moieties [13].
The solubility of the PAA-cholesterol conjugate was
determined in water and in n-pentanol the solvent selected
for the electrospraying. The surface tension of the polymer
solutions in water was measured using a Kruss Ring platinum
tensiometer K10 (Hamburg).
The zeta potential (ZP) values of the conjugate were
determined in aqueous solutions at increasing pH values,
ranging from 4.0 to 7.0, to verify the polymer charge
distribution as function of the pH. A 90 Plus instrument
(Brookhaven, NY, USA) was used to determine the elec-
trophoretic mobility and the zeta potential of the polymer.
For the determinations, the aqueous solutions of the polymer
were placed in the electrophoretic cell, where an electric
field of about 14 V/cm was applied. Each value reported
is the average of ten measurements. The electrophoretic
mobility measured was converted into Zeta Potential using
the Smoluchowski equation [17].
The PAA-solution conductibility in water was deter-
mined using a conductometer (Orion, Boston, USA).
2.5. Hemolytic Activity Determination of PAA-Cholesterol
Conjugate. The haemolytic activity of the PAA-cholesterol
conjugate was evaluated on human blood. Diﬀerent percent-
ages (2%, 4%, 7%, 10%, and 15% w/v) of polymer were
added in a erythrocytes suspension (30% v/v) phosphate
buﬀer, pH 7.4. A sample containing only a suspension of
erythrocytes (30% v/v) in phosphate buﬀer pH 7.4 was used
as blank. In addition a blank sample containing an excess
of ammonium chloride was prepared to obtain complete
erythrocyte hemolysis as hemolytic control.
After 90 minutes of incubation at 37◦C the samples were
centrifuged at 1500 rpm for 10 minutes and the supernatant
was analyzed using a Lambda 2 Perkin-Elmer spectropho-
tometer at a wavelength of 543 nm. The percentage of
hemolysis was calculated versus the 100% hemolysis control.
2.6. Preparation of PAA-Cholesterol Nanoparticles. To pre-
pare PAA-cholesterol nanoparticles the electrospraying appa-
ratus previously described was used. Preliminary experi-
ments were carried out to select the process parameters
suitable to obtain spherical nanoparticles with the PAA-
cholesterol conjugate. Diﬀerent parameters were varied to
tune the process; flow rate of 15, 10, and 5 μL min−1 and
electric field of 20, 25, and 30 KV were mainly investigated.
The experimental conditions selected were a flow rate of
5 μL min−1 and an electric field of 20 KV applied between the
capillary tip and an aluminum plate. The selected distance
from metal tip to collecting plate was 15 cm. A solution of
PAA-cholesterol conjugate in n-pentanol (1% w/w) was pre-
pared and supplied to the capillary nozzle with a 5 μL min−1
flow. During free flight the organic solvent evaporated
and solid nanoparticles collected on the plate. To obtain
fluorescent-labelled nanoparticles Rhodamine B was added
in the polymer pentanol solution (0.05% w/v). The same
process parameters were applied during electrospraying.
2.7. Preparation of Tamoxifen-Loaded PAA-Cholesterol
Nanoparticles. Tamoxifen-loaded PAA-cholesterol nanopar-
ticles were prepared by dissolving the drug (5 mg/mL) in the
conjugate n-pentanol solution (10 mg/mL) under stirring.
The solution was then electrosprayed to obtain the drug
loaded PAA-cholesterol nanoparticles using the same process
parameters selected to obtain blank nanoparticles.
2.8. Quantitative Determination of Tamoxifen. The amount
of tamoxifen-loaded into the nanoparticles was determined
after addition of 2.0 mL of phosphate buﬀer pH 7.4 con-
taining 20 mg of citric acid to a weighed amount of drug-
loaded nanoparticles (2 mg). After vortex and centrifuge for
5 minutes at 5000 rpm, 2 mL of ethanol and 0.5 mL of water
were added to the precipitate. After stirring and separation
the supernatant was analyzed by HPLC.
Tamoxifen content was determined using an HPLC
system consisting of Shimadzu liquid chromatograph (Shi-
madzu, Kyoto, Japan) equipped with an SDP 10A variable
wavelength ultraviolet detector and a CR6A integrator. A
Lichrospher C-18, 5 μm (Merck, Darmstadt, Germany),
25 cm × 4.6 mm ID reversed-phase column was used.
The column was eluted with a mobile phase containing
methanol/water/triethylamine (89/11/1, v/v). The eluent was
run at rate of 1 mL/min and monitored at 265 nm following
injected volumes of 20 μL of tamoxifen standard solutions
and samples. The calibration curve was found to be linear
in the range 0.05–30μg/mL. Each sample was analyzed in
triplicate.
2.9. Characterization of the PAA-Cholesterol Nanoparticles.
The average diameters and polydispersity indices of the three
nanoparticle formulations were determined after dispersion
of the samples in filtered water by photocorrelation spec-
troscopy (PCS) using a 90 Plus instrument (Brookhaven, NY,
USA) at a fixed angle of 90◦ and a temperature of 25◦C. The
polydispersity index indicates the size distribution within a
nanoparticles population. The electrophoretic mobility and
zeta potential of the formulations were determined using a 90
Plus instrument (Brookhaven, NY, USA). For zeta potential
determination, samples of the formulation were placed in the
electrophoretic cell, where an electric field of about 15 V/cm
was applied. Each sample was analyzed at least in triplicate.
The electrophoretic mobility measured was converted into
zeta potential using the Smoluchowski equation [17].
The nanoparticles morphology was evaluated by Scan-
ning Electron Microscopy (SEM) (Leica Stereoscan 410,
Wetzlar, Germany) and fluorescent microscopy. To perform
SEM a thin layer of particles was mounted on a copper
stud, which was then sputter coated with gold (SCD 050,
Lewica, Wetzlar, Germany) for 60 seconds under vacuum at
a current intensity of 60 mA. The gold-coated particle layer
was scanned using the accelerating voltage scanning of 20 kV.
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Figure 2: Chemical structure of the PAA-cholesterol conjugate.
2.10. Thermal Analysis of Nanoparticles. Diﬀerential scan-
ning calorimetry (DSC) analysis was carried out using
a DSC7 diﬀerential scanning calorimeter (Perkin-Elmer,
Conn, USA) equipped with a TAC7/DX instrument con-
troller. The instrument was calibrated with indium for
melting point and heat of fusion. A heating rate of 10◦C/min
was employed in the 30–120◦C temperature range. Standard
aluminium sample pans (Perkin-Elmer) were used; an empty
pan was used as reference standard. Blank nanoparticles,
tamoxifen-loaded nanoparticles, and tamoxifen powder (3-
4 mg) were weighed in conventional aluminium pans, and
analyses were performed under nitrogen purge; triple runs
were carried out for each sample.
2.11. In Vitro Release Kinetics of Tamoxifen. A multicom-
partmental rotating cell was used to evaluate the in vitro
release profile of tamoxifen. A tamoxifen aqueous suspension
1.17 mM as control and tamoxifen-loaded nanoparticles at
the same concentration dispersed in water were prepared,
and 1 mL of each was placed in the donor compartment.
A cellulose dialysis membrane with cutoﬀ at 12,000–14,000
was chosen to separate the compartments. The receptor
compartment was filled with 1 mL of pH 5.5 0.1 M citrate
buﬀer. Each experiment lasted 24 h. At fixed times, the
receptor buﬀer was completely withdrawn and replaced
with fresh citrate buﬀer. The withdrawn samples were
then analyzed by HPLC. The experiment was performed in
triplicate.
2.12. Internalization Study of PAA-Cholesterol Nanoparti-
cles. The cellular uptake of PAA-cholesterol fluorescent
nanoparticles was evaluated through confocal laser scanning
microscopy on Vero cell. Exponentially growing cells were
plated and cultured overnight in 24-well plates on glass
coverslips; the cell monolayers were incubated with appro-
priated dilutions of PAA-cholesterol fluorescent nanoparticle
suspension for 1 h and then extensively washed with PBS for
observation of live cells. Confocal sections were taken on an
inverted Zeiss LSM510 fluorescence microscope.
2.13. Cytotoxicity Assay. To test the cytotoxic eﬀect of
tamoxifen-loaded nanoparticles, MCF-7 cells were seeded in
a 96-well plate at a density of 1.2 × 104/well; the next day
they were treated with increasing concentrations, ranging
from 1 to 40 μM, of free tamoxifen and tamoxifen-loaded
nanoparticles. Treatment with equal concentrations of blank
nanoparticles was made in order to rule out the possibility of
any cytotoxic eﬀect ascribable to the delivery system.
After 24, 48, and 72 hours of incubation, cell viability
was determined by the CellTiter 96 Proliferation Assay Kit
(Promega, Madison, Wls, USA) according to the manu-
facturer’s instructions. Absorbances were measured using
a Microplate Reader (Model 680, BIORAD) at 490 nm.
The eﬀect on cell viability of the formulation at diﬀerent
concentrations was expressed as a percentage, by comparing
treated cells with cells incubated with culture medium alone.
The 50% cytotoxic concentration (CC50) values and the 95%
confidence intervals (CIs) were determined using the Prism
software (GraphPad Software, San Diego, CA).
3. Results
Firstly the new PAA-cholesterol conjugate was in vitro
characterized. The percentage of cholesterol was determined
by NMR resulting in 8% w/w.
For the electrospraying process is necessary an organic
solvent in which the PAA-Cholesterol conjugate is very
soluble. For this purpose 1-pentanol (b.p. = 137.5◦C) in
which the conjugate is soluble more than 2% w/v was
selected.
The conjugate is amphiphilic for the presence of choles-
terol in the structure. The surface tension of the PAA-
cholesterol conjugate in water at pH 6.0 was determined, and
it is reported in Figure 3. PAA-cholesterol showed a CMC in
water of about 2 mg/mL.
Zeta potential measurements demonstrated that PAA-
cholesterol is positively charged in aqueous solution with a
value of +21 mV at pH 7.0 and the positive charge increase
lowering the pH value to 4.0. The conjugate conductibility in
water was 74.8 μS.
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Figure 3: Surface tension of PAA-cholesterol conjugate in water.
Table 1: Characteristics of PAA-cholesterol nanoparticles.
Formulation d ± SD (nm) Poly-index PZ ± SD (mV)
PAA-
cholesterol
nanoparticles
223.2 ± 10.0 0.29 21.28 ± 2.76
PAA-
cholesterol
fluorescent
nanoparticles
362.8 ± 23.8 0.15 17.89 ± 1.32
PAA-
cholesterol
tamoxifen
nanoparticles
247.0 ± 17.7 0.26 14.86 ± 0.99
No significant haemolytic activity was observed for PAA-
cholesterol conjugate after 90 minutes of incubation in blood
at pH 7.4 up to a concentration of 15% w/v.
Spherical solid PAA-cholesterol nanoparticles formed
easily using an electric field of 20 KV and a flow of
5 μL min−1. The nanoparticle sizes were mainly tuned by the
control of electrospraying flow rate and polymer concentra-
tion.
The physicochemical characteristics of PAA-cholesterol
nanoparticles are reported in Table 1.
All the PAA-cholesterol conjugate nanoparticles showed
sizes lower than 500 nm with a quite narrow size distribution
and a positive Zeta Potential. The loaded nanoparticles
had sensible greater sizes and a decrease of the Zeta
potential values demonstrating the presence of incorporated
molecules in the nanoparticle structure.
SEM analyses showed that PAA-cholesterol nanoparticles
are spherical with smooth surfaces and confirmed their sizes.
The blank PAA-cholesterol nanoparticles image is reported
in Figure 4.
A fluorescent PAA-cholesterol formulation was also
prepared by the electrospraying process using Rhodamine B
as fluorescent marker to evaluate the nanoparticle cell inter-
nalization. The morphology of the fluorescent formulation
is reported in Figure 5. The fluorescent nanoparticles were
easily internalized in Vero cells (Figure 6).
SEM analysis confirmed sizes and shape of tamoxifen-
loaded PAA-cholesterol nanoparticles.
10 μm
Figure 4: SEM image of blank PAA-cholesterol nanoparticles.
Figure 5: Fluorescent PAA-cholesterol nanoparticles containing
Rhodamine B (fluorescent microscopy).
The incorporation of the drug did not aﬀect the shape
and the smooth surface of nanoparticles as shown in
Figure 7.
As it is possible to note in the figure the presence of
the drug could aﬀect the physicochemical characteristics of
the PAA-cholesterol solution favouring a partial coalescence
of the droplet. Decreasing the amount of tamoxifen, well-
separated nanoparticles were obtained (data not shown).
Tamoxifen-loaded PAA-cholesterol nanoparticles
showed a drug loading of about 40% w/w and the encapsula-
tion eﬃciency of about 90%.
Thermal analysis of tamoxifen-loaded nanoparticles did
not show the endothermic peak at about 97◦C related to
the drug melting. The disappearance of the melting peak in
the DSC profile indicates that the drug can be dispersed in
the polymer matrix. The PAA-cholesterol conjugate did not
show thermal change in this temperature range. The DSC
thermograms of the tamoxifen-loaded nanoparticles and of
tamoxifen are reported in Figure 8.
The in vitro release profile of tamoxifen from the drug-
loaded nanoparticle showed a slow release over time without
initial burst eﬀect indicating that the drug is mainly incor-
porated in the PAA-cholesterol matrix and not adsorbed
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(a) (b)
Figure 6: Internalization of fluorescent PAA-cholesterol nanoparticles on Vero cells analysed by confocal laser scanning microscopy.
10 μm
Figure 7: SEM image of In vitro release of the formulations.
12011010090807060504030
Temperature (◦C)
11.57
15
20
25
30
35
40
45
50
55
60
62.61
H
ea
t
fl
ow
en
do
u
p
(m
W
)
Tamoxifen
Tamoxifen-loaded nanoparticles
Figure 8: Thermal analysis of tamoxifen and tamoxifen-loaded
nanoparticles.
on particle surface. After 6 h about 26% of tamoxifen
was released from the PAA-cholesterol nanoparticles. On
the contrary about 15% of tamoxifen from aqueous drug
suspension diﬀused after 6 h (Figure 9).
3.1. Cytotoxicity Assay. To assess the activity of the formu-
lation, MCF-7 cells were incubated with solutions contain-
ing blank nanoparticles or tamoxifen-loaded nanoparticles,
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Tamoxifen free
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Figure 9: In vitro release of tamoxifen from the formulations.
having the same nanoparticle concentration. Free tamoxifen
was used as positive control. As free tamoxifen was diluted
in DMSO, corresponding volumes of DMSO were also
added for comparison. After 24, 48, and 72 hours from
the beginning of treatment, cells were analyzed by MTS
colorimetric assay to test cell viability.
As shown in Figures 10(a), 10(b), and 10(c), tamoxifen-
loaded nanoparticles exhibited a more pronounced
concentration-dependent cytotoxicity than free tamoxifen
at each time point analyzed. The finding that blank
nanoparticles did not show any cytotoxic eﬀect even at high
concentrations rules out their contribution to the increased
activity of the formulation and confirmed the absence of
residues.
Notably, cytotoxic eﬀect measured for those samples
that received volumes of tamoxifen greater than 2 μL (2%
v/v) seems mostly ascribable to the presence of DMSO, as
indicated by the treatment with this solvent alone.
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Figure 10: Cell viability of MCF-7 breast cancer cells incubated
for 24, 48, and 72 h (a, b, and c panels, resp.) with free tamox-
ifen (Tamoxifen), tamoxifen-loaded nanoparticles (tamoxifen-NP),
empty nanoparticles (NP), or DMSO. Each bar represents the mean
of three samples ± SD.
4. Discussion
Electrospraying (electrohydrodynamic spraying) is a pro-
cess of simultaneous droplet generation and charging by
means of electric field [9]. Production of particles of
uniform size can be accomplished by generation of cone-
jet mode. This mode of spraying is very sensitive to any
change in liquid properties, and the droplet size can vary
unexpectedly with parameter changes. By the selection of
suitable process parameters the production in a single step
of solid nanoparticles using a PAA-cholesterol conjugate as
matrix was possible. The new PAA conjugate containing
8% of cholesterol is soluble either in water or in organic
solvents with a CMC of about 2 mg/mL. Because of its
amphiphilic nature it is particularly suitable to produce
nanoparticles by electrospraying [13]. The surface tension of
the solution can aﬀect the nanoparticle formation; generally
it was shown that, decreasing the surface tension of a
solution, there is a decrease in the particle sizes with a
corresponding increase in standard deviation of the particle
sizes distribution [18]. Surface charge density and surface
tension play important roles in the process. When the surface
charge density is low, the Rayleigh limit, the maximum
limit of surface charge density when the electrostatic forces
exceed surface tension, is never reached. Another possibility
is that the surface charge density of the droplets is high, so
the Rayleigh limit is reached immediately or after solvent
evaporation and droplets disintegrate (Coulomb fission),
forming small charged droplets. In the process the Coulomb
fission should be avoided because droplets of uniform size
are required [11, 19]. The PAA-cholesterol nanoparticles are
positive charged showing that during the droplet shrinking
the hydrophilic region remains on the surface, while the
cholesterol molecules can be oriented inside the droplets.
Reproducible PAA-cholesterol nanoparticles with sizes
lower than 300 nm and spherical shape from pentanol
solution were obtained in one single step.
The eﬀect of conductivity on particle formation has
also been investigated [20]. The increase of a solution
conductivity from μS/cm to mS/cm resulted in a marked
reduction of the particle size due to the Coulomb fission.
Tamoxifen is a hydrophobic molecule with a low water
solubility (0.4 mg/mL), a high hygroscopicity and UV light
sensitivity. Its solubility in pentanol reached 2 mg/mL.
Tamoxifen-loaded PAA-cholesterol nanoparticles formed
by electrospray maintaining a mean diameter lower than
300 nm. The drug is incorporated in the polymer matrix as
DSC and in vitro release studies showed. The absence of an
initial burst eﬀect confirmed the incorporation of tamoxifen
inside the polymer matrix. Hydrophobic interaction between
cholesterol and hydrophobic portion of tamoxifen molecules
could favour the incorporation of the drug in the internal
lipophilic region. The drug probably remains molecularly
dispersed in the PAA-cholesterol conjugate matrix without
crystallizing. The disappearance of the melting peak of the
drug in the DSC profile can confirm this hypothesis.
The electrospraying process tuned employs n-pentanol,
an organic solvent with boiling point of 137.5◦C in which
the conjugate is soluble. It is important to assess that this
solvent is completely removed otherwise the electrosprayed
nanoparticles might be toxic to cells.
Therefore we tested the blank nanoparticles and the
results showed no cytotoxicity up to a concentration of
20 μM. This behaviour indicates that the conjugate nanopar-
ticles are not toxic as previously reported [13] and that
no n-pentanol remains incorporated in the polymer matrix
but it evaporates during the flight and nanoparticle for-
mation. The data are in agreement with pentanol residues
determined previously by gas chromatography in the stearic
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acid:ethylcellulose particles (4.5 : 0.5 w/w). The pentanol
content was 0.2 milligrams per gram of lipid based particles
[11].
According to previous report [21], we found that MCF7
cells are highly sensitive towards DMSO. Indeed, volumes
equal to or higher than 2 μL (2% v/v) result in a cytotoxic
eﬀect that partially overlaps the one observed in cells
treated with free tamoxifen diluted in DMSO. Therefore, this
“background” cytotoxicity leads to an overestimation of the
free tamoxifen activity, although the CC50 value we measured
is comparable to the ones presented in the literature for free
tamoxifen diluted in DMSO [22]. By contrast, tamoxifen-
loaded PAA-cholesterol nanoparticles showed a clear dose-
dependent cytotoxic activity, completely ascribable to the
drug. Considering that the CC50 value of free tamoxifen
is overestimated, the cytotoxic potency of the tamoxifen
nanoparticle formulation is even more attractive.
5. Conclusion
Solid polymeric nanoparticles with spherical shape and
smooth surface were obtained using a new PAA-cholesterol
conjugate by electrospraying, a cost eﬀective technique.
In this work electrospraying parameters were tuned to
obtain PAA-cholesterol nanoparticles avoiding fiber forma-
tion, particularly varying flow rate and voltage applied to the
nozzle.
The new PAA-cholesterol conjugate is suitable to pro-
duce nanoparticles by electrospraying in the absence of
excipients and in powder form in a single step. The
PAA-cholesterol nanoparticles show small size, spherical
shape, and good drug loading. Tamoxifen-loaded in PAA-
cholesterol nanoparticles showed a slow release over time due
to the incorporation in the conjugate matrix.
The PAA-cholesterol nanoparticles did not show any
toxic eﬀects. The tamoxifen-loaded nanoparticles showed an
enhanced cytotoxicity in comparison to the free drug.
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